Risk for definite neuroleptic malignant syndrome. A prospective study in 223 consecutive in-patients
- PMID: 1355693
- DOI: 10.1192/bjp.161.2.254
Risk for definite neuroleptic malignant syndrome. A prospective study in 223 consecutive in-patients
Abstract
The occurrence of neuroleptic malignant syndrome (NMS) was studied prospectively in two series of consecutive psychiatric in-patients (n = 223). The first group (n = 120) suffered from schizophrenia and was treated only with haloperidol. The second group (n = 103) was treated with diverse neuroleptics. All patients were on a single antipsychotic agent with no anticholinergic drug as prophylaxis. The incidence of full NMS per admission and first neuroleptic exposure was 5/223 (2.2%). Patients with bipolar affective disorder and those treated with injections were significantly over-represented in the NMS group.
Comment in
-
Neuroleptic malignant syndrome.Br J Psychiatry. 1992 Nov;161:722-3. doi: 10.1192/bjp.161.5.722c. Br J Psychiatry. 1992. PMID: 1422640 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical